No.35024/26/2019-Policy II Government of India Ministry of Chemicals & Fertilizers Department of Pharmaceuticals

Shastri Bhawan, New Delhi Dated October, 2019

То

Pharmexcil, FICCI, CII, ASSOCHAM, PHD Chamber, IPA, IDMA, BDMA, FOPE, OPPI, AIMED, MTal, CIPI

Subject:- 5th India Pharma & Medical Device Awards

Sir(s)/Madam(s),

I am directed to say that Government of India, Ministry of Chemicals & Fertilizers, Department of Pharmaceuticals has decided to confer 5th India Pharma/Medical Device Awards during India Pharma 2020 & India Medical Device 2020. The categories/indicators for these Awards are attached as Annexure.

2. You are requested to disseminate the same amongst members of your organizations. Separate nominations for each category (along with supporting documents) may be sent to the undersigned. The last date for receipt of nominations is 20th November, 2019. No nomination will be accepted after the last date.

Encl:- As above

Yours faithfully,

NE

Under Secretary to the Government of India

Tel: 23383392

Email:-navin.26@nic.in

Copy to:-Senior Technical Director (NIC)- for uploading the same on the Website of Department of Pharmaceuticals

Contd..p/2

Copy (along with enclosures) to:-

Chairman(NPPA), CMD(KAPL), CMD(IDPL), MD(BCPL), MD(HAL), MD(RDPL), CEO(BPPI)

Copy (along with enclosures) also to:-

PS to Shri D.V. Sadananda Gowda, Hon'ble Minister(C&F), PS to Shri Mansukh Mandaviya, Hon'ble MoS(C&F), PSO to Secretary(Pharma), Consultant to JS(NR), Consultant to JS(RT), PA to (EA), Consultant to Director(JT), Consultant to Director (DK), DS(MKB), DS(AVL), DS (PK), DD(Policy), US(PSU), US(IFD), US(NIPER), US(Pricing), US (MD)

Criteria/Indicators for India Pharma and India Medical Device Awards

1. India Pharma Leader Award:

	Criteria	Indicators	Dolovant information/
		maicators	Relevant information/ Documents to be
			furnished.
a.	Sales Turnover Growth in % (25% weightage)	 Cumulative growth over last 3 years i.e. % increase in sale in Year 3 as compared to Year 1. Highest of all entries received to have full marks and others proportionate 	Audited sales' figures for the last three financial years, duly certified by Company Secretary.
b.	Turnover of manufacturing in own plants as a Percentage of total turnover (25% weightage)	- Highest of all entries received to have full marks and others proportionate	Audited figures on item wise production in terms of quantity and value for different Pharma products manufactured in their own manufacturing facilities, in the previous year duly certified by Company Secretary
C.	Percentage of Sales of NLEMs vis-a-vis total Sales of Pharma products (20% weightage)	- Highest of all entries received to have full marks and others proportionate	Audited figures of sales of NLEMs for last financial year, duly certified by Company Secretary
d.	Number of products launched in the last year (10% weightage)	- Highest of all entries received to have full marks and others proportionate	List of products launched in the last year, duly certified by the Company Secretary.
е	Percentage of expenditure on R&D vis-a- vis total Annual Sales turnover averaged over 3 years (20% weightage)	- Highest of all entries received to have full marks and others proportionate	Audited figures of expenditure on R&D incurred as a % of total sales, during last 3 financial years, duly certified by Company Secretary

A one page brief about the company along with name of important products being produced and its therapeutic significance

2. India Pharma Bulk Drug Company of the Year Award :

(Critoria			
	Criteria	Indicators	Relevant information/ Documents to be furnished	
a.	Increase in Sales in % terms over previous year (40% weightage)	- Highest of all entries received to have full marks and others proportionate	The Company should indicate item-wise production and	
b.	Sales of Bulk Drugs, for use in manufacture of NLEM drugs as percentage of total Sales (30% weightage)	 Highest of all entries received to have full marks and others proportionate 	List of Bulk Drugs, together with item-wise production and sales figures, which are used in production of NLEMs, for the last financial year, duly certified by Company Secretary	
C.	Increase in R&D expenditure on bulk drugs as Percentage over the previous financial year (30% weightage)	Highest of all entries received to have full marks and others proportionate	Expenditure on R&D related to Bulk Drugs for the last 2 financial years, duly certified by Company Secretary.	

A one page brief about the company along with name of important products being produced and its therapeutic significance

3. India Pharma Innovation of the Year Award:

Criteria	Indicators	Relevant information/ Documents to be furnished
a. Number of patents files and commercialised during the last 3 financial years 1) No. of product patents filed - 25% 2) No. of product patents granted- 25% 3) No. of product patents commercialised- 25% 4) Percentage of patents /innovations commercialised during the last 3 financial years pertaining to NLEM drugs. (25% weightage)	received to have full marks and others proportiona te	 No. of process and products patents filed during the last 3 financial years, duly certified by Company Secretary. No. of patents commercialised by the Company during the year, duly certified by Company Secretary. No. of patents assigned to other entities in India and overseas, duly certified by Company Secretary.
A one page brief about the company along with	· ·	party octorotary.

A one page brief about the company along with name of important products being produced and its therapeutic significance

4. India Pharma Corporate Social Responsibility (CSR) Programme of the Year Award:

Relevant information/ Documents to be furnished - Details of CSR activities undertaken - Details of activities undertaken - Details of activities undertaken under Corporate Social Responsibility - Total expenditure incurred on these activities for the last 3 years, duly certified by Company Secretary. - Geographical coverage of the CSR activities and approximate impact on the number of people.			
Details of CSR activities undertaken Details of activities undertaken under Corporate Social Responsibility Total expenditure incurred on these activities for the last 3 years, duly certified by Company Secretary. Geographical coverage of the CSR activities and approximate impact on the number of people.			
undertaken under Corporate Social Responsibility Total expenditure incurred on these activities for the last 3 years, duly certified by Company Secretary. Geographical coverage of the CSR activities and approximate impact on the number of people.	D	Documents to be furnished	
- The Jury to decided		undertaken under Corporate Social Responsibility Total expenditure incurred on these activities for the last 3 years, duly certified by Company Secretary. Geographical coverage of the CSR activities and approximate impact on the	
	- The Jury to decided		

A one page brief about the company along with name of important products being produced and its therapeutic significance

Category 5- India Medical Devices Company of the Year Award

	Criteria	Indicators	Relevant information/
			Documents to be furnished
1	2	3	4
a.	Sales Turnover increase in % over previous year (50% weightage)	 Percentage growth in Sales turnover over previous year. Highest of all entries received to have full marks and others proportionate 	 Give details of the Medical Devices and their sales turnover during the last 2 years, duly certified by Company Secretary. Contents of different Medical Devices produced in terms of value of content achieved.
b.	R&D expenditure as a % of Sales (50% weightage)	 Percentage R&D expenditure on Sales turnover Highest of all entries received to have full marks and other proportionate 	 R&D expenditure in terms of percentage of sales incurred during the last year, duly certified by Company Secretary. Audited figures of expenditure on R&D in last year, duly certified by Company Secretary.

A one page brief about the company along with name of important products being produced

Category 6- India Pharma Swachhta Champion Award

The award would be open to all Pharma Industry, traders, Medical Devices Industry and their Associations in both rural & urban areas.

	C 1		
	Criteria	Indicators	Relevant information/
			Documents to be
-	2		furnished
-		3	4
	(including expenditure on waste disposal making available drinking water maintenance of toilets, display boards hoardings on use of water, sanitation hygiene etc) vis-à-vis total annual turnover (2018-19) (Weightage 20%)	received to have full marks and others proportionate	Annual Report, duly
b	Increase in expenditure on Swachhata (including expenditure on waste disposal, making available drinking water, maintenance of toilets, display boards, hoardings on use of water, sanitation, hygiene etc)in % terms over the previous year (Weightage 20%)	received to have full marks and others proportionate	Audited figures as per Annual Report, duly certified by the Company Secretary
С	Percentage of Safai Karamchari (including persons deployed for waste disposal) vis a vis total employee of the unit (Weightage 10%)	Highest of all entries received to have full marks and others proportionate	As per Annual Report of the company, duly; certified by the
d	Number of units of Gents toilets/urinals per 100 persons (Weightage 10%)	Highest of all entries received to have full marks and others proportionate	As per Annual Report of the company, duly; certified by the
е	Number of units of Ladies toilets/urinals per 100 persons (Weightage 10%)	Highest of all entries received to have full marks and others proportionate	As per Annual Report of the company, duly; certified by the
f	% Increase in number of toilets/urinals constructed during 2018-19 over previous year (Weightage 10%)	Highest of all entries received to have full marks and others	As per Annual Report of the company, duly; certified by the
g	Number of dustbins installed per 100 persons (Weightage 10%)	Highest of all entries received to have full marks and others	As per Annual Report of the company, duly; certified by the
h		Highest of all entries received to have full marks and others	Company Secretary As per Annual Report of the company, duly; certified by the Company Secretary

A one page brief about the company along with name of important products being produced and its therapeutic significance.

Note:

- Comparisons would be made based on audited results of the Financial Year 2018 19 and previous years
- Unaudited results would not be considered for evaluation
- No company would be conferred an Award in 2 categories in the same year. In case such a situation arises, the award appearing first in the list of Awards would be conferred and the second award would be given to the applicant with the next highest marks.
- The same category of award would not be conferred to the same company for 2 years in succession.
